Lead Product(s) : Voruciclib,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MEI Pharma Updates Study Of Oral CDK9 Inhibitor Voruciclib with Venetoclax
Details : ME-522 (voruciclib), a selective CDK9 inhibitor, is being evaluated with venetoclax for the treatment of relapsed and refractory acute myeloid leukemia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 26, 2024
Lead Product(s) : Voruciclib,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voruciclib,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ME-522 (voruciclib) is an orally administered cyclin-dependent kinase 9 (“CDK9”) inhibitor with potential to treat Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : Voruciclib,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voruciclib,Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Voruciclib and support its potential as a therapeutic option for KRAS mutated cancers in combination with direct inhibitors of KRAS.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 04, 2021
Lead Product(s) : Voruciclib,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voruciclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2018
Lead Product(s) : Voruciclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voruciclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Dana-Farber Cancer Institute | Norris Cotton Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2014
Lead Product(s) : Voruciclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Dana-Farber Cancer Institute | Norris Cotton Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voruciclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Melanoma Research Foundation Breakthrough Consortium
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2013
Lead Product(s) : Voruciclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Melanoma Research Foundation Breakthrough Consortium
Deal Size : Inapplicable
Deal Type : Inapplicable